The IFN-λ4 Conundrum: When a Good Interferon Goes Bad

被引:18
|
作者
Onabajo, Olusegun O. [1 ]
Muchmore, Brian [1 ]
Prokunina-Olsson, Ludmila [1 ]
机构
[1] NCI, Lab Translat Genom, Div Canc Epidemiol & Genet, NIH, 8717 Grovemont Circle, Bethesda, MD 20892 USA
来源
基金
美国国家卫生研究院;
关键词
IFN-lambda; 4; type III interferon; SOCS1; USP18; regulation; HCV; CHRONIC HEPATITIS-C; LAMBDA; 4; NEGATIVE REGULATOR; ANTIVIRAL ACTIVITY; SOCS3; EXPRESSION; HCV; RECEPTOR; SUPPRESSOR; THERAPY; ALPHA;
D O I
10.1089/jir.2019.0044
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Since its discovery in 2013, interferon lambda 4 (IFN-lambda 4) has received a reputation as a paradoxical type III IFN. Difficulties in detecting IFN-lambda 4, especially in secreted form even led to questions about its existence. However, the genetic ability to generate IFN-lambda 4, determined by the presence of the rs368234815-Delta G allele, is the strongest predictor of impaired clearance of hepatitis C virus (HCV) infection in humans. Significant modulation of IFN-lambda 4 activity by a genetic variant (P70S) supports IFN-lambda 4, and not other type III IFNs encoded in the same genomic locus, as the primary functional cause of the association with HCV clearance. Although the ability to produce IFN-lambda 4 is associated with decreased HCV clearance, the recombinant IFN-lambda 4 is active against HCV and other viruses. These observations present an apparent conundrum-when and how does a presumably good IFN, with anti-HCV activity, interfere with the ability to clear HCV? In this review, we discuss findings that suggest potential mechanisms for explaining this conundrum.
引用
收藏
页码:636 / 641
页数:6
相关论文
共 50 条
  • [31] Inborn errors of interferon (IFN)-mediated immunity in humans: insights into the respective roles of IFN-α/β, IFN-γ, and IFN-λ in host defense
    Zhang, Shen-Ying
    Boisson-Dupuis, Stephanie
    Chapgier, Ariane
    Yang, Kun
    Bustamante, Jacinta
    Puel, Anne
    Picard, Capucine
    Abel, Laurent
    Jouanguy, Emmanuelle
    Casanova, Jean-Laurent
    [J]. IMMUNOLOGICAL REVIEWS, 2008, 226 : 29 - 40
  • [32] Editorial commentary: Endothelial-to-mesenchymal transition: When the good one goes bad
    Zhang, Yixuan
    Cai, Hua
    [J]. TRENDS IN CARDIOVASCULAR MEDICINE, 2017, 27 (06) : 394 - 396
  • [33] When good cholesterol goes bad: mass spectrometric approaches for the analysis of dysfunctional HDL
    Heinecke, Jay
    [J]. CHEMICAL RESEARCH IN TOXICOLOGY, 2007, 20 (12) : 2014 - 2015
  • [34] When good water goes bad: How it happens, clinical consequences and possible solutions
    Lonnemann, G
    [J]. BLOOD PURIFICATION, 2004, 22 (01) : 124 - 129
  • [35] When A Good Impression Goes Bad:The Effect of Goal Changes on Repeated Attitudes Enquires
    Li, Xiuping
    [J]. ADVANCES IN CONSUMER RESEARCH VOL XXXIV, 2007, 34 : 452 - 452
  • [36] When good cholesterol goes bad: Mass spectrometric approaches for the analysis of dysfunctional HDL
    Heinecke, Jay
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2007, 234
  • [37] When Good Food Goes Bad Television Network News and the Spinach Recall of 2006
    Nucci, Mary L.
    Cuite, Cara L.
    Hallman, William K.
    [J]. SCIENCE COMMUNICATION, 2009, 31 (02) : 238 - 265
  • [38] When the Skull Base Goes Bad
    Hogan, D.
    O'Connor, A.
    Rawluk, D.
    McConn-Walsh, R.
    [J]. IRISH JOURNAL OF MEDICAL SCIENCE, 2016, 185 : S511 - S511
  • [39] Erratum: When biotech goes bad
    John Hodgson
    [J]. Nature Biotechnology, 2016, 34 (6) : 666 - 666
  • [40] IFN-β, but not IFN-α, is Responsible for the Pro-Bacterial Effect of Type I Interferon
    Shaabani, Namir
    Vartabedian, Vincent F.
    Nguyen, Nhan
    Honke, Nadine
    Huang, Zhe
    Teijaro, John R.
    [J]. CELLULAR PHYSIOLOGY AND BIOCHEMISTRY, 2021, 55 (03) : 256 - 264